FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Apellis Pharmaceuticals: Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and...

May 24
Last Trade: 40.61 0.93 2.34

Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress WALTHAM,...Read more

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with...

May 23
Last Trade: 1.30 0.02 1.56

FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patients FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate...Read more

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 23
Last Trade: 3.90 0.04 1.04

Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansion Early low-dose cohorts showing meaningful improvement in patient symptoms and biological evidence...Read more

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and...

May 24
Last Trade: 4.12 -8.06 -66.17

Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a medical conference in the second half of 2024 Avutometinib and defactinib combination have continued...Read more

Guardant Health: FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening...

May 23
Last Trade: 25.52 3.01 13.37

The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood test that meets...Read more

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer...

May 23
Last Trade: 0.30 -0.03 -10.06

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has...Read more

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...


Biggest Gainers

CompanyChangeLast Trade
Merus 15.92 36.12 $59.99
Insulet 9.28 5.43 $180.07
Third Harmonic Bio 6.79 94.31 $13.99
Intuitive Surgical 6.46 1.62 $404.85
DaVita 6.29 4.76 $138.54
Vertex Pharmaceuticals 6.15 1.36 $456.95
argenx 6.05 1.68 $367.07
Stryker 5.42 1.64 $335.54
Regeneron Pharmaceuticals 4.45 0.45 $985.02
Inspire Medical Systems 3.90 2.52 $158.72
Corbus Pharmaceuticals 3.64 8.80 $45.02
HCA Healthcare 3.38 1.07 $318.70
West Pharmaceutical 3.07 0.93 $331.66
Morphic Therapeutic 3.04 10.95 $30.80
National HealthCare 3.03 3.05 $102.27
Guardant Health 3.01 13.37 $25.52
Penumbra 2.97 1.56 $193.66
TransMedics 2.76 2.01 $140.29

Highest Volume

CompanyVolumeLast Trade
Cue Health 157,310,979 $0.09
OneMedNet 135,103,512 $2.30
Ginkgo Bioworks 44,439,193 $0.66
Onconetix 37,431,938 $0.18
Pfizer 19,448,799 $28.88
Verastem Oncology 19,338,969 $4.12
Electromedical Technologies 19,119,264 $0.001
Bristol-Myers Squibb 16,767,102 $41.24
Novavax 12,655,595 $15.50
CVS Health 10,867,810 $55.54
Walgreens Boots Alliance 10,384,270 $16.03
NLS Pharmaceutics 9,968,286 $0.17
NovaBay Pharmaceuticals 9,409,949 $0.13
Summit Therapeutics 9,103,571 $3.38
Medtronic 8,569,600 $82.29
Johnson & Johnson 8,330,545 $146.97
PacBio 7,969,210 $1.87
Therapeutic Solutions 7,565,891 $0.0007
Sharps Technology 7,023,017 $0.21
  • Upcoming FDA Catalysts

    • Abeona Therapeutics (NASDAQ: ABEO) PDUFA Date

      May 25, 2024
    • Abeona Therapeutics (NASDAQ: ABEO) PDUFA Date

      May 25, 2024
    • Catalyst Pharmaceuticals (NASDAQ: CPRX) PDUFA Date

      June 4, 2024
    • Genfit (NASDAQ: GNFT) PDUFA Date

      June 10, 2024
    • Amgen (NASDAQ: AMGN) PDUFA Date

      June 12, 2024
    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      June 15, 2024

Featured Stock


Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...


Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is installed...


Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...


Featured Stock


Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....


Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: